MUFG Americas’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,880
| Closed | -$376K | – | 30 |
|
|
2022
Q3 | $376K | Buy |
1,880
+13
| +0.7% | +$2.6K | 0.01% | 328 |
|
|
2022
Q2 | $272K | Buy |
1,867
+51
| +3% | +$7.43K | 0.01% | 359 |
|
|
2022
Q1 | $297K | Buy |
1,816
+61
| +3% | +$9.98K | 0.01% | 357 |
|
|
2021
Q4 | $298K | Buy |
1,755
+89
| +5% | +$15.1K | 0.01% | 359 |
|
|
2021
Q3 | $315K | Buy |
1,666
+8
| +0.5% | +$1.51K | 0.01% | 349 |
|
|
2021
Q2 | $281K | Buy |
1,658
+418
| +34% | +$70.8K | ﹤0.01% | 361 |
|
|
2021
Q1 | $175K | Buy |
1,240
+266
| +27% | +$37.5K | ﹤0.01% | 409 |
|
|
2020
Q4 | $127K | Buy |
974
+250
| +35% | +$32.6K | ﹤0.01% | 418 |
|
|
2020
Q3 | $106K | Buy |
724
+166
| +30% | +$24.3K | ﹤0.01% | 426 |
|
|
2020
Q2 | $82K | Buy |
+558
| New | +$82K | ﹤0.01% | 442 |
|
|
2013
Q3 | – | Sell |
-3,200
| Closed | -$99K | – | 1182 |
|
|
2013
Q2 | $99K | Buy |
+3,200
| New | +$99K | ﹤0.01% | 1041 |
|